3Q filing for Alkermes' once-monthly aripiprazole on top-line data
This article was originally published in Scrip
Executive Summary
Alkermes is set to file for US approval of its once-monthly aripiprazole formulation, aripiprazole lauroxil in the third quarter based on positive top-line Phase III data.